Portland, OR -- (ReleaseWire) -- 06/05/2014 --China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2012, sales on the Chinese drug market have reached RMB 926.1billion (about US$147 billion) reported by the «2012: Report of China Pharmaceutical Market» published by Chinese Academy of Social Sciences. It is estimated that it will exceed RMB 1,000 billion by 2013. A series of factors, such as an increasingly ageing population, accelerating growth of urban population as well as expansion of healthcare covering urban and rural, will grow the Chinese drug market with a growth rate over 20 percent per annum in next three years. China is expected to become the second largest drug market in the world by 2015.

To Get Full Access of Report visit: http://www.bigmarketresearch.com/regulations-for-imported-drug-registration-market

Since the reform and open door policy implemented by the Chinese authorities in the late 1970s, the door of the Chinese drug market began opening up to the world step by step, which gave a fillip to the imported drugs from overseas pharmaceutical manufacturers and producers. By 2012, sales of imported drugs have shared one fourth on the Chinese drug market. As China joins the World Trade Organization (WTO) and integrates more completely into the global economy, it will further open the door of a lucrative drug market for overseas pharmaceutical companies. More and more overseas pharmaceutical manufacturers and producers expect to enter such drug market and seize a larger part of such drug market. To enter such a lucrative drug market, the first obstacle faced by overseas pharmaceutical manufacturers and producers is how to file the application for their imported drug registration with Chinese pharmaceutical authorities. In China, the process of application and approval for imported drug registration is very complex, because the Chinese pharmaceutical authorities administer and control this process by exorbitant administrative measures and regulations, moreover, these exorbitant administrative regulations are variable and lack of transparency.

Therefore, a comprehensive and thorough knowledge of the latest Chinese regulations for imported drug registration has been become an essential prerequisite for overseas pharmaceutical manufacturers and producers to achieve a successful application for their products entry into the Chinese drug market. In despite of since the drug registration implemented by the Chinese pharmaceutical authorities on December 1, 2002, its regulatory regime has experienced countless changes, and become increasingly compatible with international standards, in turn, its ongoing consolidation will eventually contribute to a healthier market environment. The Chinese Pharmaceutical authority promulgated the last “Measures for the Administration of Drug Registration” on July 10 2007, and the last “Measures” entered into force since October 1, 2007. However, the practical operations for application and approval of imported drug registration have been constantly changed, because the amendment of “Measures” is sluggish. Under such circumstance, Access China Management Consulting Ltd published the China Pharmaceutical Guidebook (2013 Edition): Latest Chinese Regulations for Imported Drug Registration. The aim of this guidebook is to guide overseas pharmaceutical manufacturers and producers to achieve a successful application and approval for their imported drug registration. This guidebook is composed of main four parts as the following.

A Comprehensive Guidance of Imported Drug Registration
A Guidance of Registration Application for Imported Chemical Drugs
A Guidance of Registration Application for Imported Biological Products
A Guidance of Registration Application for Imported Natural Medicines and Traditional Chinese Medicines
Part I provides a comprehensive guidance of imported drug registration, which introduces an overview of the main responsibilities and organization structure of the Chinese pharmaceutical authority ---- China Food and Drug Administration (CFDA), the comprehensive regulations for imported drug registration in China, from the classification of drugs, definitions relating to application for imported drug registration, the application and approval for imported drugs and repackaging of imported drugs, the supplementary application and re-registration for imported drugs, the clinical investigation for application of imported drug registration to the time limits in drug registration, as well as the procedures of application and approval for imported drug registration, including the procedures of the initial application and approval for imported drugs, the supplementary application and approval for imported drugs, and the application and approval for clinical trials relating to imported drugs. All such knowledge in Part I is essential to achieve a successful application and approval for imported drug registration in China.

In China, like in other Western countries, the pharmaceutical authority ---- CFDA requests applicant to submit complicate and reliable materials for application of imported drug registration. Therefore, to achieve a successful application and approval for imported drug registration in China, overseas pharmaceutical manufacturers and producers must understand the more depth and detailed regulations on registration application for various imported drugs.

Part II provides a guidance of registration application for imported chemical drugs, which addresses CFDA’s requirements for materials and clinical trials of application and approval for imported chemical drug registration, including radioactive pharmaceuticals, from the classification of drug registration formulated by the CFDA, the material items for application of chemical drug registration, the requirements of material items for application of chemical drug registration, the requirements of clinical trial for application of chemical drug registration to the material and clinical trial requirements for application of radioactive pharmaceuticals.

Part III provides a guidance of registration application for imported biological products. The biopharmaceutical industry is one of the burgeoning industries. In the field of biopharmaceuticals, vast knowledge awaits people to explore. The biopharmaceuticals are diversified and complex. In China, the development of biopharmaceutical industry is later and behind the developed countries. Just for this reason, the requirements of materials and clinical trials for registration application of biopharmaceuticals stipulated by the Chinese pharmaceutical authority are far from systematic and uniform. In China, the CFDA divided the biopharmaceuticals for registration application into two classifications, i.e. the therapeutic biological products and the prophylactic biological products. However, in the classification of therapeutic biological products, the CFDA does not provide the harmonized requirements of materials and clinical trials for registration application of biological products for the gene therapy, the somatic cell therapy and the allergic therapy, but stipulates the other guidelines for them. Therefore, the requirements for materials and clinical trials of registration application for imported gene therapeutic biological products, imported somatic cell therapeutic biological products and imported allergic therapeutic biological products are addressed based on these guidelines. Part III addresses the requirements of material items and clinical trials for registration application of imported therapeutic biological products and prophylactic biological products, as well as the imported biological products for the gene therapy, the somatic cell therapy and the allergic therapy, from the classification of therapeutic biological product and prophylactic biological product registration formulated by the CFDA, the material items for registration application of therapeutic biological products and prophylactic biological products, the requirements of material items for registration application of therapeutic biological products and prophylactic biological products, the requirements of clinical trial for registration application of therapeutic biological products and prophylactic biological products to the guideline for registration application of biological products for human gene therapy, the guideline for registration application of biological products for somatic cell therapy, and the guideline for registration application of biological products for allergic therapy.

Part IV provides a guidance of registration application for imported natural medicines and traditional Chinese medicines. The traditional medicines in Orient, especially, the traditional Chinese medicines are always regarded by occidental as mysterious medicines. Until today not only the chemical composition of traditional Chinese medicines almost can not been expressed by a precise chemical structural formula, but also the indications of the majority of traditional Chinese medicines still can not been clearly described by the modern medical terminologies. How the Chinese pharmaceutical authorities to administer the registration application for such mysterious traditional Chinese medicines? Part IV provides a detailed introduction of the CFDA’s requirements for materials and clinical trials of application and approval for imported traditional Chinese medicine. The CFDA collects the traditional Chinese medicines and the natural medicines into a category for registration application. Therefore, Part IV provides not only the introduction for registration application of the imported traditional Chinese medicines but for the natural medicines, from the classification of natural medicine and traditional Chinese medicine registration formulated by the CFDA, the material items for registration application of natural medicines and traditional Chinese medicines, the requirements of material items for registration application of natural medicines and traditional Chinese medicines to the requirements of clinical trial for registration application of natural medicines and traditional Chinese medicines.

The guidebook concludes in Part V by highlighting the significant suggestions for overseas pharmaceutical manufacturers and producers looking to achieve a successful application for their drug registration in China. Last, the appendices in Part VI include the Drug Administration Law of the People’s Republic of China, the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China, the Chinese Good Clinical Practice of Pharmaceutical Products, references, and description of Access China Management Consulting Ltd.

More and more overseas pharmaceutical manufacturers and producers expect to acquire the latest detailed information about the Chinese regulations for imported drug registration. In this guidebook, overseas pharmaceutical manufacturers and producers can easily find out every answer that they will meet question during process of application and approval for their imported drug registration in China. After have skimmed through this guidebook, audience can clearly acquire a comprehensive and thorough knowledge of the latest Chinese regulations for imported drug registration. Access China Management Consulting Ltd hopes this China Pharmaceutical Guidebook (2013 Edition) ---- Latest Chinese Regulations for Imported Drug Registration, based on full and accurate regulations and law, can help guide overseas pharmaceutical manufacturers and producers to achieve a successful application and approval for their imported drug registration in China.

Report Highlights

An overview of the main responsibilities and organization structure of the CFDA (The China Food and Drug Administration) that is current Chinese pharmaceutical authority at the central level, and takes responsible for application and approval for imported drug registration.
The comprehensive regulations for imported drug registration in China, from the classification of drugs, definitions relating to application for imported drug registration, the application and approval for imported drugs and repackaging of imported drugs, the supplementary application and re-registration for imported drugs, the clinical investigation for application of imported drug registration to the time limits in drug registration.
The procedures of application and approval for imported drug registration, including the procedures of the initial application and approval for imported drugs, the supplementary application and approval for imported drugs, and the application and approval for clinical trials relating to imported drugs.
A guidance of registration application for imported chemical drugs.
A guidance of registration application for imported biological products.
A guidance of registration application for imported natural medicines and traditional Chinese medicines.
The significant suggestions for overseas pharmaceutical manufacturers and producers looking to achieve a successful application for their drug registration in China.
Many useful resources of law and regulations, including the Drug Administration Law of the People’s Republic of China, the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China, the Chinese Good Clinical Practice of Pharmaceutical Products, the Application Form of Registration for Imported Drug, and so on.
Who should buy this report?

Companies wishing to enter a lucrative drug market in China.
Companies interested in understanding the latest Chinese regulations on application and approval for imported drug registration.
Senior executive officers engaging regulatory and registration affairs for drugs.

Table Of Content

PART I. A COMPREHENSIVE GUIDAENCE OF IMPORTED DRUG REGISTRATION
Chapter I-1. Introduction
Chapter I-2. The China Food and Drug Administration
Chapter I-3. General Regulations on Application and Approval for Imported Drug Registration
Chapter I-4. Application and Approval Procedures for Imported Drug Registration

PART II. A GUIDANCE OF REGISTRATION APPLICATION FOR IMPORTED CHEMICAL DRUGS
Chapter II-1. Introduction
Chapter II-2. Classification of Chemical Drug Registration
Chapter II-3. Material Items for Application of Drug Registration
Chapter II-4. Requirements of Material Items for Application of Drug Registration
Chapter II-5. Requirements of Clinical Trial for Application of Drug Registration
Chapter II-6. Material and Clinical Trial Requirements for Radioactive Pharmaceuticals

PART III. A GUIDANCE OF REGISTRATION APPLICATION FOR IMPORTED BIOLOGICAL PRODUCTS
Chapter III-1. Introduction
Chapter III-2. Classification of Therapeutic Biological Product Registration
Chapter III-3. Material Items for Application of Therapeutic Biological Product Registration
Chapter III-4. Requirements of Material Items for Application of Therapeutic Biological Product Registration
Chapter III-5. Requirements of Clinical Trial for Application of Therapeutic Biological Product Registration
Chapter III-6. Classification of Prophylactic Biological Product Registration
Chapter III-7. Material Items for Application of Prophylactic Biological Product Registration
Chapter III-8. Requirements of Material Items for Application of Prophylactic Biological Product Registration
Chapter III-9. Requirements of Clinical Trial for Application of Prophylactic Biological Product Registration
Chapter III-10. Guideline for Application of Biological Products for Gene Therapy
Chapter III-11. Guideline for Application of Biological Products for Somatic Cell Therapy
Chapter III-12. Guideline for Application of Biological Products for Allergic Therapy

PART IV. A GUIDANCE OF REGISTRATION APPLICATION FOR IMPORTED NATURAL MEDICINES AND TRADITIONAL CHINESE MEDICINES
Chapter IV-1. Introduction
Chapter IV-2. Classification of Natural Medicine and Traditional Chinese Medicine Registration
Chapter IV-3. Material Items for Registration Application of Natural Medicines and Traditional Chinese Medicines
Chapter IV-4. Requirements of Material Items for Registration Application of Natural Medicines and Traditional Chinese Medicines
Chapter IV-5. Requirements of Clinical Trial for Registration Application of Natural Medicines and Traditional Chinese Medicines

PART V. CONCLUSION
Chapter V-1. Conclusion
Chapter VI-1 The Drug Administration Law of the People’s Republic of China

Similar Market Studies

Competitive Intelligence 2014: Analysis of the Global Animal Health Market, and Leading Suppliers' Marketing Tactics and Technological Know-How
http://www.bigmarketresearch.com/competitive-intelligence-2014-analysis-of-the-global-animal-healthand-leading-suppliers-ing-tactics-and-technological-know-how-market

Global Meningococcal Vaccines Market
http://www.bigmarketresearch.com/meningococcal-vaccines-market

Competitive Intelligence 2014: Global Animal Health Market Outlook and Leading Suppliers' Strategies, Marketing Tactics, and Technological Know-How
http://www.bigmarketresearch.com/competitive-intelligence-2014-global-animal-healthoutlook-and-leading-suppliers-strategies-ing-tactics-and-technological-know-how-market

Global Ophthalmic Drugs Market
http://www.bigmarketresearch.com/ophthalmic-drugs-market

About Big Market Research
With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency. With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Our research services ranges into different domains and penetrates in different verticals so that we can carter to diverse needs of various organization. Not wrong to quote that this is the hotspot for research needs of yours.Our strength is in our research analysts who with their proactive approach are able to source best and correct information which can be detrimental in organizations success. We follow six sigma standards leaving no scope for error.

COntact Us:
Sona Padman
5320 SW Macadam Avenue,
Suite 100, Portland, OR 97239
United States
Direct: +1(617)674-4143
Toll Free: +1(855)711-1555 (U.S. & Canada)
Fax: +1(855)550-5975
Email - sales@bigmarketresearch.com
Web - http://www.bigmarketresearch.com/